You are here: Home: Meet The Professors - Breast Cancer 1 | 2009: Faculty Affiliations and Disclosures
Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — Drs Perez and Winer had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Hudis — Advisory Committee: Genentech BioOncology, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi-Aventis; Consulting Agreement: Amgen Inc; Paid Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Onyx Pharmaceuticals Inc. Dr Miller — Consulting Agreements: Eli Lilly and Company, Genentech BioOncology, Roche Laboratories Inc; Paid Research: Pfizer Inc, Roche Laboratories Inc; Speakers Bureau: Genentech BioOncology, Roche Laboratories Inc. Dr Swain — Paid Travel: Sanofi-Aventis.
COMMUNITY PANEL — Drs Deutsch, Luedke, Steinecker, Tetreault, Towell and Tsarwhas had no real or apparent conflicts of interest to disclose. Dr Astrow — Advisory Committee: Ortho Biotech Products LP; Consulting Agreement: Pfizer Inc. Dr De Fusco — Speakers Bureau: AstraZeneca Pharmaceuticals LP, Novartis Pharmaceuticals Corporation. Dr Ng — Speakers Bureau: Eli Lilly and Company, Genentech BioOncology, Sanofi-Aventis. Dr Robbins — Stock Ownership: Celgene Corporation. Dr Tracy — Advisory Committee: Genomic Health Inc; Stock Ownership: Amgen Inc, Biogen Idec, Bristol-Myers Squibb Company, Eli Lilly and Company, Genentech BioOncology, Genomic Health Inc, Millennium Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc.
MODERATOR — Neil Love: Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Biogen Idec, Bristol- Myers Squibb Company, Celgene Corporation, Cephalon Inc, Eisai Inc, Eli Lilly and Company, Genentech BioOncology, Genomic Health Inc, Genzyme Corporation, GlaxoSmithKline, ImClone Systems Incorporated, Merck and Company Inc, Millennium Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Ortho Biotech Products LP, OSI Oncology, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis, Synta Pharmaceuticals Corp and Wyeth.
RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
Medical Oncologist Community Panel
Copyright © 2009 Research To Practice. All Rights Reserved